Skip to main content
SpringerLink
Log in

Therapie bronchopulmonaler Erkrankungen

  • Chapter
Praktische Arzneitherapie

  • 39 Accesses

Zusammenfassung

Die chronische Entzündung ist wesentlicher Faktor für die Entwicklung und das Fortbestehen chronisch-obstruktiver Atemwegserkrankungen. Deshalb werden inhalative Kortikosteroide bereits beim leichtgradig ausgeprägten Asthma bronchiale empfohlen ([1]; Tabelle 14.1). Für die Therapieplanung ist eine Einteilung in Schweregrade der Erkrankung hilfreich, wodurch eine rationale Stufentherapie ermöglicht wird. Ein vom Patienten zu führendes Peak-flow-Protokoll (z. B. täglich zweimalige Messung) erleichtert die Einschätzung durch Arzt und Patient wesentlich [2]. Angestrebt werden normale Peak-flow-Werte bzw. eine möglichst niedrige tägliche Varianz der Werte (<20%). Die aktuellen Therapiestrategien unterscheiden zwischen Substanzen zur Dauertherapie („Controller“), die ständig eingenommen und nur bei einer dauerhaften Änderung des Symptomschweregrades verändert werden, und Substanzen zur Bedarfsmedikation („Reliefer“), die bei Bedarf zusätzlich zur Basismedikation angewendet werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Wettengel R, Berdel D, Hofmann D, Krause J et al. (1998) Asthmatherapie bei Kindern and Erwachsenen. Med Klin 93: 639–650

    Article  CAS  Google Scholar 

  2. Magnussen H, Wettengel R (1993) Das Peak-flow-Meter. Med Klin 88: 720–723

    CAS  Google Scholar 

  3. Warner JO, Naspitz CK et al. (1998) Third international pediatric consensus statement on the management of childhood asthma. Pediatr Pulmonol 25: 1–17

    Article  PubMed  CAS  Google Scholar 

  4. Rennard SI (1998) COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 113: 235S - 2415

    Article  PubMed  CAS  Google Scholar 

  5. Lauber B (1996) Sozialmedizinische Daten zu chronisch obstruktiven Atemwegserkrankungen in der Bundesrepublik Deutschland. Atemw Lungenkrkh 22: 63–72

    Google Scholar 

  6. Madison TM, Irwin RS (1998) Chronic obstructive pulmonary disease. Lancet 352: 467–473

    Article  PubMed  CAS  Google Scholar 

  7. Crompton GK (1990) The adult patient’s difficulties with inhalers. Lung 168 (Suppl): 58–662

    Article  Google Scholar 

  8. Thorsson L, Edsbäcker S, Conradson TB (1994) Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 7: 1839–1844

    Article  PubMed  CAS  Google Scholar 

  9. Siafkas NM, Vermeire P, Pride NB, Paoletti P et al. (1995) Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J 8: 1398–1420

    Article  Google Scholar 

  10. Celli BR (1998) Standards for the optimal management of COPD: a summary. Chest 113 (4Suppl): 283S - 287S

    Article  PubMed  CAS  Google Scholar 

  11. Pauwels R, O’Byrne PM (1997) Beta 2-agonists in asthma treatment. Series Lung Biology in Health and Disease, Vol 106. Marcel Dekker, New York

    Google Scholar 

  12. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy ( FACET) International Study Group. N Engl J Med 337: 1405–1411

    Google Scholar 

  13. McDevitt DG, Wallace RJ, Roberts A, Whitfield CR (1975) The uterine and cardiovascular effects of salbutamol and practolol during labour. Br J Obstet Gynaecol 82: 442–448

    Article  PubMed  CAS  Google Scholar 

  14. Walker SR, Evans ME, Richards AJ, Paterson JW (1972) The clinical pharmacology of oral and inhaled salbutamol. Clin Pharmacol Ther 13: 861–867

    PubMed  CAS  Google Scholar 

  15. Nyberg L (1984) Pharmakokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis 65 (Suppl 134): 149–160

    Google Scholar 

  16. Buchelt L, Rominger KL (1972) The pharmacokinetics and metabolism of berotec (fenoterol) in man. Medical Proceedings 18: 15–20

    Google Scholar 

  17. Heel RC, Brogden RN, Speight TM, Avery GS (1978) Fenoterol: A review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 15: 3–32

    Google Scholar 

  18. Walter SD, Sackett DL, Shannon HS, Levine M et al. (1991) Fenoterol and fatal asthma. Lancet 337: 186–187

    Article  PubMed  CAS  Google Scholar 

  19. Crane J, Pearce N, Flatt A, Burgess C et al. (1989) Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1: 917–922

    Article  PubMed  CAS  Google Scholar 

  20. Ukena D, Keller A, Sybrecht GW (1994) Theophyllin: Neues zu einem bewährten Medikament. Die duale Wirkung in der Therapie des Asthma bronchiale. Med Klin 89: 668–674

    Google Scholar 

  21. Rall TW (1990) Drugs used in the treatment of asthma. In: Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg) Pharmacological basis of therapeutics. Pergamon Press, Elmsford, New York, p 618

    Google Scholar 

  22. Barnes PJ, Pedersen S (1993) Efficacy and safety of inhaled corticosteroids in Asthma. Am Rev Respir Dis 148: S1 - S26

    Article  PubMed  CAS  Google Scholar 

  23. Kamada AK, Szefler SJ (1998) How should inhaled glucocorticoids be compared? J Allergy Clin Immunol 99: 735–737

    Article  Google Scholar 

  24. Boorsma M, Andersson N, Larsson P, Ullman A (1996) Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 9: 1427–1432

    Article  PubMed  CAS  Google Scholar 

  25. Toogood JH, Lefcoe NM, Haines DSM, Jennings B et al. (1977) A graded dose assessment of the efficiency of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 59: 298308

    Google Scholar 

  26. Capewell S, Reynolds S, Suttleworth D, Edwards C et al. (1990) Purpura and dermal thinning associated with high dose inhaled corticosteroids. Brit Med J 300: 1548–1551

    Article  PubMed  CAS  Google Scholar 

  27. Greenberger PA, Patterson R (1983) Beclomethasone dipropionate for severe asthma during pregnancy. Ann Intern Med 98: 478–480

    Article  PubMed  CAS  Google Scholar 

  28. Chaplin MD, Rooks W, Swenson EW, Cooper WC et al. (1980) Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 27: 402–413

    Article  PubMed  CAS  Google Scholar 

  29. Horwitz RI, McGill KA, Busse WW (1998) The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 157: 1363–1371

    Article  PubMed  CAS  Google Scholar 

  30. Winsel K (1992) Antixoidative and entzündungshemmende Eigenschaften von Ambroxol. Pneumologie 46: 461–475

    PubMed  CAS  Google Scholar 

  31. Mezzetti M, Colombo L, Marini mg, Crusi Vet al. (1990) A pharmacokinetc study on pulmonary tropism of ambroxol in patients under thoracic surgery. J Emerg Surg Intens Care 13: 179–185

    Google Scholar 

  32. Janes J, Routledge PA (1992) Recent developments in the management of paracetamol (acetaminophen) poisoning. Drug safety 7: 170–177

    Article  PubMed  CAS  Google Scholar 

  33. Irwin RS, Curley FJ, Bennett FM (1993) Appropriate use of antitussives and protussives. A practical review. Drugs 46: 80–91

    Google Scholar 

Download references

Authors
  1. P. Entzian
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover, D-30623, Hannover, Deutschland

    J. C. Frölich

  2. Medizinische Fakultät, Institut für Klinische Pharmakologie, Technische Universität Dresden, Fiedlerstr. 27, D-01307, Dresden, Deutschland

    W. Kirch

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Entzian, P. (2000). Therapie bronchopulmonaler Erkrankungen. In: Frölich, J.C., Kirch, W. (eds) Praktische Arzneitherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09398-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09398-6_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-66071-2

  • Online ISBN: 978-3-662-09398-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation